loader image
Sunday, February 1, 2026
45.5 F
McAllen
- Advertisement -

Urging caution on AI in mammography

Translate to Spanish or other 102 languages!

Doctors should proceed cautiously, because similar technological leaps previously led to higher rates of false-positive tests and over-treatment. Newswise Image
Doctors should proceed cautiously, because similar technological leaps previously led to higher rates of false-positive tests and over-treatment. Newswise Image

Mega Doctor News

- Advertisement -

 By University of California, Los Angeles (UCLA), Health Sciences 

Newswise — Analyzing breast-cancer tumors with artificial intelligence has the potential to improve healthcare efficiency and outcomes. But doctors should proceed cautiously, because similar technological leaps previously led to higher rates of false-positive tests and over-treatment.

That’s according to a new editorial in JAMA Health Forum co-written by Joann G. Elmore, MD, MPH, a researcher at the UCLA Jonsson Comprehensive Cancer Center, the Rosalinde and Arthur Gilbert Foundation Endowed Chair in Health Care Delivery and professor of medicine at the David Geffen School of Medicine at UCLA.

- Advertisement -

“Without a more robust approach to the evaluation and implementation of AI, given the unabated adoption of emergent technology in clinical practice, we are failing to learn from our past mistakes in mammography,” the JAMA Health Forum editorial states. The piece, posted online Friday, was co-written with Christoph I. Lee, MD, MS, MBA, a professor of radiology at the University of Washington School of Medicine.

One of those “past mistakes in mammography,” according to the authors, was adjunct computer-aided detection (CAD) tools, which grew rapidly in popularity in the field of breast cancer screening starting more than two decades ago. CAD was approved by the FDA in 1998, and by 2016 more than 92% of U.S. imaging facilities were using the technology to interpret mammograms and hunt for tumors. But the evidence showed CAD did not improve mammography accuracy. “CAD tools are associated with increased false positive rates, leading to overdiagnosis of ductal carcinoma in situ and unnecessary diagnostic testing,” the authors wrote. Medicare stopped paying for CAD in 2018, but by then the tools had racked up more than $400 million a year in unnecessary health costs.

“The premature adoption of CAD is a premonitory symptom of the wholehearted embrace of emergent technologies prior to fully understanding their impact on patient outcomes,” Elmore and Lee wrote.

The doctors suggest several safeguards to put in place to avoid “repeating past mistakes,” including tying Medicare reimbursement to “improved patient outcomes, not just improved technical performance in artificial settings.”

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

CDC Tops 1 Million Voluntary Participants in Traveler Genomic Surveillance Program

The Centers for Disease Control and Prevention (CDC) today announced that its Traveler-Based Genomic Surveillance (TGS) program has surpassed one million voluntary participants, marking a significant milestone in the United States' ability to detect and respond to emerging public health threats at our borders.

STHS Heart Launches Heart Saver Initiative with $49 Cardiac CT Screenings Thru Feb. 28th

Rising rates of obesity, hypertension and diabetes in the United States have resulted in an increasing prevalence of heart disease across the nation, especially among young adults.

Simple Habits That Make Falling Asleep Easier

Mega Doctor News CLEVELAND CLINIC - Struggling to fall asleep at night once...

Annual VAMOS Golf Tournament Drives Funding for First-Generation College Students

The Valley Alliance of Mentors for Opportunities and Scholarships (VAMOS) recently announced that it will host its 30th Annual VAMOS Golf Tournament, on Saturday, March 7, 2026 at Champion Lakes Golf Course in McAllen, Texas.
- Advertisement -
×